文献速递肝胆胰外科围术期管理与 ERAS

白蛋白结合型紫杉醇联合吉西他滨-顺铂化疗后根治性手术治疗局部晚期胆管癌的临床可行性

Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
PubMed 文献 · Surgery · 2022-11-23

可测量病灶患者客观缓解率60.8%,疾病控制率91.9%;59.7%转为可切除,56.6%接受根治性手术,R0切除率91.8%。

要点

  • 三药化疗在局部晚期胆管癌中客观缓解率60.8%,疾病控制率91.9%
  • 59.7%患者化疗后转为可切除,56.6%接受根治性手术,R0切除率91.8%
  • 术后主要并发症率15.1%,术后死亡率2.7%,手术组12个月生存95.9%

核心结论

  • 白蛋白结合型紫杉醇联合吉西他滨-顺铂三药化疗通过高缓解率实现降期,可作为局部晚期胆管癌的诱导治疗。

主要发现

  • 可测量病灶患者(57.4%)中客观缓解率为60.8%,疾病控制率为91.9%。
  • 术后主要并发症率为15.1%,术后死亡2例(2.7%)。
  • 化疗后手术组12个月总生存率显著高于单纯化疗组(95.9% vs 76.8%;P < .001)。

临床怎么用

  • 对局部晚期胆管癌可考虑该三药方案作为诱导化疗,争取降期后根治性手术。

局限性

  • 单中心回顾性设计,样本量有限,选择偏倚可能存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study was conducted to evaluate the clinical feasibility of nab-paclitaxel plus gemcitabine-cisplatin triplet chemotherapy in patients with locally advanced cholangiocarcinoma in real-world practice. METHODS: We retrospectively reviewed patients with locally advanced cholangiocarcinoma who were treated with nab-paclitaxel plus gemcitabine-cisplatin between October 2019 and August 2021 at a single institution. The initial diagnosis of cholangiocarcinoma was histologically confirmed. RESULTS: One hundred twenty-nine patients were included in this study. Among the patients with a measurable lesion (57.4%), the objective response rate and disease control were 60.8% and 91.9%, respectively. Seventy-seven patients (59.7%) were determined as resectable after triplet chemotherapy, but 73 (56.6%) underwent subsequent curative surgery. The major postoperative complication rate was 15.1%, and there were 2 postoperative mortalities (2.7%). There were 6 complete remission cases (8.2%) in the final pathology. The R0 resection was achieved in 67 patients (91.8%). Despite the initial locally advanced cholangiocarcinoma, a pathologic T stage of less than T2 was reported in 67 patients (91.8%). Fifty-two patients (71.2%) had no lymph node metastasis. Patients who underwent surgery after triplet chemotherapy had significantly higher 12-month overall survival (95.9% vs 76.8%; P < .001) than those treated with chemotherapy alone. CONCLUSION: Nab-paclitaxel plus gemcitabine-cisplatin chemotherapy demonstrated a down-staging effect through a high response rate, indicating that this triplet chemotherapy is feasible as induction therapy in patients with locally advanced cholangiocarcinoma.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Choi SH, Kang I, Lee SH, et al. Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma. Surgery. 2022. PMID: 36435652. doi:10.1016/j.surg.2022.09.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。